Dyskinesia News and Research

RSS

Long-term effects of two common drugs for early Parkinson's similar

A study published online in the Archives of Neurology involving two common drugs used to treat early-stage Parkinson's disease shows that, while the drugs each have advantages and disadvantages, the overall impact tends to even out over a long period of treatment.

10 Mar 2009

FDA requires boxed warning and risk mitigation strategy for metoclopramide-containing drugs

The U.S. Food and Drug Administration announced today that manufacturers of metoclopramide, a drug used to treat gastrointestinal disorders, must add a boxed warning to their drug labels about the risk of its long-term or high-dose use.

1 Mar 2009

Safinamide significantly improved motor function in patients with advanced Parkinson's disease

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, and its partner Newron Pharmaceuticals SpA has announced that the first Phase III trial of investigational agent safinamide as adjunctive therapy to levodopa (study 016) met its primary endpoint by increasing daily "ON" time in mid- to late-stage Parkinson's disease patients with motor fluctuations by 1.3 hours.

5 Feb 2009

Lilly receives complete response letter for Olanzapine LAI for treatment of schizophrenia

Eli Lilly and Company has announced that it received a complete response letter from the U.S. Food and Drug Administration (FDA) for olanzapine long-acting injection (LAI) for acute and maintenance treatment of schizophrenia in adults.

7 Jan 2009

Deep brain stimulation helps advanced Parkinson's disease patients

Patients with advanced Parkinson disease (PD) who received deep brain stimulation treatment had more improvement in movement skills and quality of life after six months than patients who received other medical therapy, but also had a higher risk of a serious adverse events, according to a study in the January 7 issue of JAMA.

6 Jan 2009

Paliperidone palmitate shows positive results for treatment of schizophrenia

Paliperidone palmitate, an investigational long-acting therapy (LAT) demonstrated statistically significant symptom control compared with placebo according to the results of a 13-week study.

14 Dec 2008

Addex Parkinson's product progressing in early clinical trials

Addex Pharmaceuticals has announced that it has completed the first part of a two-part Phase I clinical trial to evaluate the newly developed modified release formulation of ADX48621. ADX48621 is scheduled to start a Phase IIa proof of concept study for the treatment of levodopa associated dyskinesia in Parkinson's disease during the first half of 2009.

15 Oct 2008

Expert warns of anti-psychotic drugs use in children

Research from Britain is suggesting that an increasing number of children are being prescribed anti-psychotic drugs to treat a range of conditions which are not licensed for use in children.

9 Apr 2008

AstraZeneca submits sNDA for SEROQUEL XR for treatment of major depressive disorder

AstraZeneca has announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for once- daily SEROQUEL XR (quetiapine fumarate) Extended-Release Tablets to seek approval for the treatment of major depressive disorder (MDD) as monotherapy, adjunct therapy, and maintenance therapy in adult patients.

1 Mar 2008

Lilly knocked back by FDA on Zyprexa for schizophrenia treatment

Eli Lilly and Company has received a not approvable letter from the U.S. Food and Drug Administration for Zyprexa long-acting injection (olanzapine LAI) for the treatment and maintenance treatment of schizophrenia in adults, the company announced.

28 Feb 2008

AstraZeneca submits sNDAs for SEROQUEL XR for bipolar symptoms

AstraZeneca has announced that the company has submitted two separate supplemental New Drug Applications (sNDAs) to the U.S. Food and Drug Administration (FDA) for once-daily SEROQUEL XR (quetiapine fumarate) Extended-Release Tablets to seek approval for the treatment of manic episodes associated with bipolar disorder and the treatment of depressive episodes associated with bipolar disorder.

3 Jan 2008

Chlamydomonas reinhardtii genome holds clues for renewable energy, the environment and human health

University of Minnesota researchers contributed to a national effort to sequence the genome of an ancient, one-celled organism that will help advance research in a broad range of areas, from biofuels to restoring the environment to understanding a variety of human diseases.

12 Oct 2007

Primary ciliary dyskinesia linked to heterotaxy

The same genetic defect that causes a rare respiratory disease may also lead to some types of congenital heart disease, according to a study from the University of North Carolina at Chapel Hill School of Medicine.

14 Jun 2007

Clinical study results on bifeprunox for schizophrenia

Solvay Pharmaceuticals, Inc., Wyeth Pharmaceuticals and Lundbeck A/S presented clinical study results on bifeprunox, an investigational treatment for adult patients diagnosed with schizophrenia, at the 2007 annual meeting of the American Psychiatric Association.

24 May 2007

CleveMed receives approval to market motor assessment system

Cleveland Medical Devices has received Food and Drug Administration (FDA) clearance to market Kinesia, a quantitative motor assessment system.

2 May 2007

FDA approves INVEGA treatment for schizophrenia

The U.S. Food and Drug Administration (FDA) has approved INVEGA (paliperidone) Extended-Release Tablets, a new once-daily, atypical antipsychotic, for the long-term maintenance treatment of schizophrenia.

30 Apr 2007

Novel two-step mechanism ensures that all cilia beat in unison

Cilia, tiny hair-like structures that propel mucus out of airways, have to agree on the direction of the fluid flow to get things moving. Researchers at the Salk Institute for Biological Studies discovered a novel two-step mechanism that ensures that all cilia beat in unison.

24 Apr 2007

Newborns with respiratory distress should be evaluated for primary ciliary dyskinesia

Reviewing published reports, Ferkol and Margaret Leigh, M.D., professor of pediatrics at the University of North Carolina at Chapel Hill (UNC), found that neonatal respiratory distress was a common clinical symptom of PCD, a chronic airway disease that affects about 1 in 15,000 children.

20 Feb 2007

Older schizophrenia drugs cheaper and work just as well

According to a new study an older antipsychotic drug has been found to be both cheaper and as effective for some patients with schizophrenia as the newer drugs on the market.

4 Dec 2006

Parkinson's patients stomach new drug better than conventional meds

Several studies conducted at Baylor College of Medicine (BCM) in Houston show that a new kind of orally disintegrating tablets provides improved symptom relief for patients with Parkinson's disease.

13 Jun 2006